Lyra Therapeutics (LYRA) Current Leases (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Current Leases of $4.8 million in Q4 2025, up 2.86% on a QoQ basis from $4.7 million in Q3 2025, and up 16.91% YoY from $4.1 million in Q4 2024.
Lyra Therapeutics (LYRA) Current Leases (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Current Leases for 7 consecutive years, with $4.8 million the latest figure, recorded in Q4 2025.
- Current Leases for Q4 2025 came in at $4.8 million, up 16.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.8 million (up 16.91% YoY), and the FY2025 annual result was $4.8 million, up 16.91% from the prior year.
- Current Leases for Q4 2025 stood at $4.8 million, up from $4.7 million in the prior quarter.
- The five-year high for Current Leases was $5.4 million in Q4 2023, with the low at $654000.0 in Q3 2022.
- A 5-year average of $2.7 million and a median of $1.8 million in 2023 frame the typical range for Current Leases.
- Across the five-year window, Current Leases slumped 37.83% in 2022 and surged 250.81% in 2023, its largest moves.
- Lyra Therapeutics' Current Leases stood at $1.1 million in 2021, then surged by 44.23% to $1.5 million in 2022, then surged by 250.81% to $5.4 million in 2023, then slipped by 24.16% to $4.1 million in 2024, then gained by 16.91% to $4.8 million in 2025.
- The last three Current Leases figures came in at $4.8 million (Q4 2025), $4.7 million (Q3 2025), and $4.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 4.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.82 Mn |
| Sep 30, 2025 | 4.68 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.24 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 4.50 Mn |
| Dec 31, 2023 | 5.43 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2022 | 654,000.00 |
| Jun 30, 2022 | 926,000.00 |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.01 Mn |